1499 results about "Adjunctive treatment" patented technology

A safe and effective treatment to curtail and cure autism spectrum disorders has been described in this invention using insulin, IGF-1, with multiple known adjuvant therapeutic agents, as well as other pharmaceutical, biochemical, nurticeuticals, and biological agents or compounds delivered through the olfactory mucosal region of the nose and external auditory meatus.

This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherin A and B are further defined in the application.

Methods and apparatus for orthodontic treatment planning that involve determining an initial position of an orthodontic structure, determining an altered position, and generating response surface data using a mathematical relationship between the positions. The mathematical relationship may be defined by a number of parameters useful for determining one or more of the stress, strain, force, and moment associated with movement of the orthodontic structure. The mathematical relationship between the initial position and the altered position may be defined using a finite element analysis, empirically determined, or using other computational methodologies such as a finite difference methodology. The mathematical relationship may also be defined using an analytical methodology, such as elasticity and / or plasticity methodologies. Response surface data may be generated as a teaching aid, treatment planning aid, table, or other useful form, which may be useful, for example, for designing an orthodontic appliance, verifying an orthodontic prescription, and / or planning the prescription.

The invention provides a therapeutic system comprising:a console, wherein the console comprises a controller and an energy generator;a therapeutic device comprising: an operational head configured for transmitting the energy output from to a biological tissue; and a memory device comprising control instructions, wherein said control instructions comprise instructions for controlling the console;a reversible memory operable linkage linking the memory device to the controller; anda reversible connector configured for operably linking the energy generator to the operational head.Optionally, the energy generator is a generator of ablation energy or heat energy (e.g. RF generator) and the control instructions comprise instructions for controlling the output of the energy generator. Optionally, the control instructions comprise one or more parameters of energy output or an algorithm configured for controlling the energy output. Optionally, the system further comprises one or more secondary therapeutic devices and the control instructions comprise instructions for controlling the one or more secondary therapeutic devices. Optionally, the system further comprises one or more sensors configured for sensing parameters of energy output or biological or environmental effects of the energy output and the control instructions comprise instructions for controlling the energy output and / or secondary therapeutic devices based on the parameters of energy output or biological or environmental effects. In some embodiments, one advantage provided by the present invention is the use of a single console with a plurality of interchangeable reversibly connected therapeutic devices.

This invention relates to aryl carbonyl derivativeswhich are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

The invention relates to a nutrient healthcare product and a method for preparing the same, in particular to a compound vegetable healthcare product and a method for preparing the same. The compound vegetable nutrient powder of the invention consists of the following components in part by weight: 0.1 to 100 parts of dried vegetable powder, 0 to 10 parts of alga-type plant regulating powder, 0 to 96 parts of auxiliary component, 0 to 5 parts of natural flavoring agent and 0 to 5 parts of food additive. The preparation method adopts a simple production process and is suitable for industrialized production, and the product prepared by the method is rich in nutrition and stable in quality, meets the demands of people on various nutrients, regulates the intestines and stomach, improves enterogastric peristalsis, enhances in vivo metabolism of sulfur-contained substances, avoids the adverse effects of human body caused by malnutrition and unbalanced nutrition and prevents and helps to treat diseases such as ulcerative stomatitis, diabetes and constipation. The product has also the advantages of convenience for carrying and long storage period.

Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.

An implantable medical device (IMD) identifies lead performance issues and provides alternative lead configurations to continue with the programmed therapy. In the absence of an appropriate alternatively lead configuration, the IMD determines alternative mechanisms to provide a similar therapy or to determine a secondary therapy.

The invention belongs to the field of medicinal chemical engineering, and relates to application of 2-arylimidazo[1,2-alpha]pyridine-3-acetamide derivatives to prepare medicines for controlling PTSD (posttraumatic stress disorder). Specifically, the invention relates to application of a compound shown as a formula I and pharmaceutically salts thereof to prepare medicines for controlling and / or treating and / or auxiliarily treating PTSD, wherein the compound and the pharmaceutically salts thereof are used as TSPO (translocator protein) ligands. The TSPO ligands such as the compounds shown as the formula I and the pharmaceutically salts are capable of effectively preventing and / or treating and / or auxiliarily treating PTSD, and can be used to prevent medicines for controlling and / or treating and / or auxiliarily treating PTSD.

Methods and compositions containing oxytocin or an oxytocin analog, specifically carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of the invention are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders.

A method for computer-assisted medical navigation and / or pre-operative treatment planning includes detecting the current position of a patient or a part of a patient's body and the positions of medical treatment devices or treatment-assisting devices. The detected positional data can be assigned to body structure data, in order to jointly use the body structure data in assignment with the positional data, within the context of assisting the treatment. The body structure data can be used which is obtained based on a three-dimensional generic model, where the model is adapted by two-dimensional data linking with patient-characteristic, two-dimensional detection data.

A system for treating a lesion site of a patient is disclosed. The system includes a cannula having a lumen, a conduit in communication with said lumen, an introducer stylet removably disposed within said cannula, a resecting device selectively insertable within said cannula, and an adjuvant treatment device selectively insertable within said cannula.

The invention discloses a polypeptide medicament sustained release microsphere or a microcapsule preparation with uniform grain size, a preparation method thereof and application. The average grain size of the microsphere or the microcapsule preparation is between 50 nanometers and 100 microns, and the grain size distribution coefficient CV value is less than 20 percent. The polypeptide medicament has a definite structure, has functions of therapy or adjuvant therapy of type-2 diabetes, and is preferably one or more of GLP-1, Exenatide, Exendin-4 and derivatives and analogs thereof. The microsphere or the microcapsule preparation uses a microsphere or a microcapsule with uniform grain size as a substrate to prepare the polypeptide medicament into a sustained release preparation through an embedding mode, and by changing the grain size of the microsphere or the microcapsule, the sustained release cycle is adjustable between one week and one month, and the microsphere or the microcapsule preparation can be applied to the therapy or the adjuvant therapy of the type-2 diabetes and body weight control. Besides, the microsphere or the microcapsule preparation has the advantages of simple preparation process and mild preparation course, and can protect the biological activity of the embedded polypeptide medicament.

Colorectal cancer patients with operable tumors must decide whether to receive adjuvant therapy after surgical resection in order to reduce their chances of recurrence. Current clinical guidelines are crudely based on the stage of the disease, as well as a few other clinicopathologic features. The instant invention integrates data from these clinicopathologic features with data on multiple biomarkers using advanced informatic methods to provide a far more accurate prediction of recurrence than the current guidelines. The instant invention consists of a panel of biomarker assays plus an algorithm into which the scored biomarker data, as well as standard clinicopathologic data, is entered. A tumor sample from an individual patient is submitted for test, and an individualized report is produced with a prognostic score that accurately reflects the patient's risk of recurrence. This helps guide the patient and his / her oncologist in their choice of whether to receive adjuvant treatment. Low-risk patients are spared the unnecessary toxicities associated with cytotoxic treatments, and high-risk patients are given the best chance for a cure, maximizing both life expectancy and quality of life.

This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

Apparatus and method for performing interstitial laser therapy and adjunctive therapy on a patient are revealed. The apparatus employs a combination of a mammography unit, an interstitial laser treatment device attached to the mammography unit and a treatment platform positioned relative to the mammography unit to enable the interstitial laser therapy to be performed. The use of the treatment platform with the mammography unit enables the interstitial laser therapy to be performed and, if necessary, adjunctive therapy to be performed in the same treatment room without transferring the patient to a new platform.

Systems and methods that treat disorders of the gastrointestinal tract by applying one or more treatment agents to tissue at or near the region where abnormal neurological symptoms or abnormal tissue conditions exist. The treatment agent is selected to either disrupt the abnormal nerve pathways and / or to alleviate the abnormal tissue conditions. The treatment agent can include at least one cytokine and / or at least one vanilloid compound to evoke a desired tissue response. The systems and methods can be used a primary treatment modality, or as a neoadjuvent or adjuvant treatment modality.

The invention provides a method for the treatment of cancer comprising administering a serotonin agent. Also provided is a method for the treatment of cachexia comprising administering a serotonin agent.

The invention provides novel compositions, methods and uses, for the diagnosis, prognosis, prediction, prevention and aid in treatment of malignant neoplasia such as breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer. Genes that are chromosomally amplified in breast tissue of breast cancer patients are disclosed. Further disclosed are chromosomally amplified genes and non-amplified genes that correlate to Taxane resistance, Taxane benefit or adverse Taxane reaction, which can be used as an aid to make therapy dicisions.

Methods and devices are described for the regulation of Transforming Growth actor (TGF)-β1, β2, and / or β3 protein gene expression in bone cells and other tissues via the capacitive coupling or inductive coupling of specific and selective electric fields to the bone cells or other tissues, where the specific and selective electric fields are generated by application of specific and selective electric and electromagnetic signals to electrodes or one or more coils or other field generating device disposed with respect to the bone cells or other tissues so as to facilitate the treatment of diseased or injured bone and other tissues. By gene expression is meant the up-regulation or down-regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are provided for the targeted treatment of injured or diseased bone and other tissue that include generating specific and selective electric and electromagnetic signals that generate fields in the target tissue optimized for increase of TGF-β1, β2, and / or β3 protein gene expression and exposing bone and other tissue to the fields generated by specific and selective signals so as to regulate TGF-β1, β2, and / or β3 protein gene expression in such tissue. The resulting methods and devices are useful for the targeted treatment of bone fractures, fractures at risk, delayed unions, nonunion of fractures, bone defects, spine fusions, osteonecrosis or avascular necrosis, as an adjunct to other therapies in the treatment of one or all of the above, in the treatment of osteoporosis, and in other conditions in which TGF-β1, β2, and / or β3 protein may be implicated.

Methods of using zonisamide as an adjunctive therapy for partial seizures are disclosed. In particular, the methods enhance the safety of patients taking pharmaceutical formulations of zonisamide by providing information that increases the awareness of pancreatitis as a possible side effect; wherein the patients and / or prescribing physicians and other medical care providers are advised to monitor for pancreatitis and employ methods that will improve the therapeutic outcome in the few patients who experience pancreatitis associated with zonisamide therapy.

The present invention relates to a new method of adjuvant therapy in the treatment of early breast cancer, comprising administering six cycles of docetaxel, doxorubicin and cyclophosphamide to a patient in need thereof, wherein said dosages have a marked therapeutic effect when compared to other adjuvant therapies.

Methods of using zonisamide as an adjunctive therapy for partial seizures are disclosed. In particular, the methods enhance the safety of patients taking pharmaceutical formulations of zonisamide by providing information that increases the awareness of pancreatitis as a possible side effect; wherein the patients and / or prescribing physicians and other medical care providers are advised to monitor for pancreatitis and employ methods that will improve the therapeutic outcome in the few patients who experience pancreatitis associated with zonisamide therapy.

The invention relates to a biological fermentation composition with an anti-cancer effect. The biological fermentation composition is prepared by using a method comprising the following steps: a, preparing a culture medium mixed solution; b, sterilizing; c, cooling; d, inoculating to obtain a fermentation solution; and e, standing to obtain the biological fermentation composition with the anti-cancer effect. The composition disclosed by the invention can be used for improving the in-vivo micro-ecological environment, balancing and regulating effective microbial communities in intestinal canals, repairing damaged cells, replenishing various in-vivo active bio-enzymes, amino acids, nucleic acids, trace elements and the like, improving the immunity of a human body, preventing diseases, effectively inhibiting cancer cells and stopping the dispersion and development of the cancer cells. Meanwhile, the biological fermentation composition can be used for improving an acidic physique to be a weak alkaline physique, is particularly suitable for the cancer crowd, the crowd with hypertension, hyperlipidemia and hyperglycemia and the fat crowd, can be prepared into various dosage forms such as pills, paste, aqueous solutions and the like, and has favorable supportive therapeutic effects on cancer, diabetes, digestive system diseases and the like.

The invention discloses a quinoline compound, and a preparation method, an intermediate, a medicinal composition and an application thereof / The invention provides a quinoline compound represented by formula 1 shown in the specification, and its pharmaceutically acceptable salts, solvates, metabolites, metabolism precursors or medicinal precursors. The quinoline compound has a good inhibition effect on tyrosine kinases C-Met, and can be used for preparing medicines for prevention, treatment or adjuvant treatment of many C-Met expression or activity related diseases, especially tumor diseases.

The invention belongs to the field of remote control and artificial intelligence and relates to an intelligent adjuvant therapy robot device for performing real-time social capability training for autism children. The device comprises a head movement driver (1), an arm movement driver (2), a device loader (3), a driving-driven wheel type chassis (4) and a casing module (7). A multi-joint combined driving mode is adopted, the collaborated driving capability of the robot for every movement joint is improved, the problem that time delay affects the interaction effect is solved, precise posture control of the robot in the random direction is achieved, a limb movement path planning function for automatically avoiding obstacles is achieved, and intelligent emotion interaction between a human and the robot and a safe and reliable family remote rehabilitation therapy model are achieved in various modes such as voice, images, touch and induction in the man-machine interactive process in response to emotion cognitive disorder which occurs universally in child patients.